Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 28:14:1264951.
doi: 10.3389/fphar.2023.1264951. eCollection 2023.

Combatting the rising costs of cancer drugs; interventions from a university hospital's perspective

Aniek Dane  1 , Roelof van Leeuwen  1 , Maaike Hoedemakers  2 , Hugo van der Kuy  1 , Stefan Sleijfer  3
Affiliations

Combatting the rising costs of cancer drugs; interventions from a university hospital's perspective

Aniek Dane et al. Front Pharmacol. .

Abstract

Rapid increase in cost continues to have negative impact on patients' accessibility to life-changing anticancer medications. Moreover, the rising cost does not equate to similar increase in medication effectiveness. We recognise our responsibility as a university hospital to tackle this imbalance and strive to provide high quality, sustainable, affordable and accessible care. An active approach in cost containment of expensive and innovative cancer drugs was adopted in our organisation to safeguard accessibility and improve quality of life for patients. In this article, we described four inverventions: 1) identify right patient and minimise overtreatment, 2) in-house medicine production for selected indications, 3) minimise medicine spillages and 4) effective procurement strategies. We call on other hospitals to take action and, favourably, to collaborate on a European level. Together, we will safeguard the current and future care of our patients.

Keywords: biomarkers; cancer drugs; drug life cycle; efficiency; precision dosing; self-manufacturing; sustainable healthcare; university hospital.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

FIGURE 1
FIGURE 1
Drug life cycle from a university hospital’s perspective.
See this image and copyright information in PMC

References

    1. Bayle A., Besse B., Annereau M., Bonastre J. (2019). Switch to anti-programmed cell death protein 1 (anti-pd-1) fixed-dose regimen: what is the economic impact? Eur. J. Cancer 113, 28–31. 10.1016/j.ejca.2019.02.016 - DOI - PubMed
    1. Brouwer W., van Baal P., van Exel J., Versteegh M. (2019). When is it too expensive? Cost-Effectiveness thresholds and health care decision-making. Eur. J. Health Econ. 20 (2), 175–180. 10.1007/s10198-018-1000-4 - DOI - PubMed
    1. Cherny N. I., Dafni U., Bogaerts J., Latino N. J., Pentheroudakis G., Douillard J. Y., et al. (2017). ESMO-magnitude of clinical benefit Scale version 1.1. Ann. Oncol. 28 (10), 2340–2366. 10.1093/annonc/mdx310 - DOI - PubMed
    1. de Wit R., Roberts J. T., Wilkinson P. M., de Mulder P. H., Mead G. M., Fosså S. D., et al. (2001). Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medical research council. J. Clin. Oncol. 19 (6), 1629–1640. 10.1200/JCO.2001.19.6.1629 - DOI - PubMed
    1. Di Maio M., Perrone F., Conte P. (2019). Real‐world evidence in oncology: opportunities and limitations. Oncol. 25 (5), e746–e752. 10.1634/theoncologist.2019-0647 - DOI - PMC - PubMed